Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07246590 · ClinicalTrials.gov registry record · Phase 3
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)
A Phase 3 study of Warts and Human Papilloma Virus (HPV), sponsored by Verrica Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
- 6
- Study locations
NCT07246590: Recruiting Phase 3 study of Warts and Human Papilloma Virus (HPV), sponsored by Verrica Pharmaceuticals.
NCT07246590 is a Phase 3 study of Warts and Human Papilloma Virus (HPV) that is actively recruiting participants, run by Verrica Pharmaceuticals. The registered enrollment target is 300 participants, above the 179-participant average among 7 other Warts trials with a reported enrollment target (68% higher). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07246590, a Phase 3 study of Warts and Human Papilloma Virus (HPV), is actively recruiting participants, sponsored by Verrica Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a Phase 3, double-blind, randomized, vehicle-controlled study (Study number VP-CW-301; referred to as COVE-2 \[Cantharidin and Occlusion in Verruca Epithelium\]) to evaluate the efficacy and safety of YCANTH (VP-102) treatment in subjects with common warts.
Primary Outcome
To evaluate the efficacy of YCANTH (VP-102) relative to Vehicle by assessing the proportion of subjects achieving complete clearance defined by complete resolution of all common warts as assessed visually by a Blinded Assessor of all treatable common warts, at the EOT Visit (Day 84).
Conditions Studied
Interventions
- COMBINATION_PRODUCT VP-102
- COMBINATION_PRODUCT Vehicle
Study Locations (6)
Texas
- The University of Texas Health Science Center at Houston - Houston
- Texas Dermatology and Laser Specialists - San Antonio
Florida
- Florida Center for Dermatology, P.A. - Saint Augustine
Indiana
- The Indiana Clinical Trials Center, PC - Plainfield
Maryland
- Anne Arundel Dermatology, PA dba Maryland Dermatology Laser Skin & Vein - Hunt Valley
Tennessee
- Tennessee Clinical Research Center, Inc. - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2025-12-17 |
| Est. Completion | 2027-06 |
| Phase | Phase 3 |
What NCT07246590 shows while recruiting
NCT07246590 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, above the 179-participant average among 7 other Warts trials with a reported enrollment target (68% higher).
The record links to 4 conditions, with Warts appearing as the primary indexed condition, and to 2 interventions - of which VP-102 is the first listed.
NCT07246590 lists 6 locations in 5 states (Texas, Florida, Indiana).
Frequently Asked Questions
What is clinical trial NCT07246590 about?
NCT07246590 is a clinical study titled "Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)". This is a Phase 3, double-blind, randomized, vehicle-controlled study (Study number VP-CW-301; referred to as COVE-2 \[Cantharidin and Occlusion in Verruca Epithelium\]) to evaluate the efficacy and safety of YCANTH (VP-102) treatment in subjects with common warts.
What is the current status of trial NCT07246590?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2025-12-17. Estimated completion is 2027-06.
What conditions does trial NCT07246590 study?
This clinical trial studies the following conditions: Warts, Human Papilloma Virus (HPV), Common Warts, Common Warts (Verruca Vulgaris).
What interventions are being tested in trial NCT07246590?
The interventions under investigation include: VP-102 (COMBINATION_PRODUCT), Vehicle (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT07246590?
This trial is sponsored by Verrica Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07246590 being conducted?
This trial has 6 study locations across Florida, Indiana, Maryland, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Warts
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
RECRUITING · Phase 1
-
Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts
RECRUITING · Phase 2
-
Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia
RECRUITING
-
Microwave Treatment of Common and Plantar Warts
ACTIVE NOT RECRUITING · NA
-
Evaluation of the Effectiveness of an Alcohol Based Hand Gel for the Reduction of Warts on the Hands
COMPLETED · NA
-
Candin Safety & Efficacy Study for the Treatment of Warts
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI